- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
October 25th, 2010
In an industry obsessed with finding the next big blockbuster, Melbourne-based Starpharma is using its technology platform to steadily accumulate wins in a broad range of markets.
Originally developed by the CSIRO's molecular research institute, Starpharma's dendrimer nanotechnology platform has seen the company sign licensing and co-development agreements with some of the world's largest pharmaceutical and medical technology companies, including Eli Lilly, Elanco and GlaxoSmithKline (GSK). In addition to developing new product pipelines, many of these companies are now applying Starpharma's technology towards improving the efficacy of existing products.
|Related News Press|
News and information
Personal cooling units on the horizon April 29th, 2016
Exploring phosphorene, a promising new material April 29th, 2016
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010